Hyderabad: American Oncology Institute at Citizens Specialty Hospital in Hyderabad successfully performed advanced external radiotherapy on an 88-year-old male patient suffering with high-risk prostate cancer. The most advanced form of radiotherapy technique, also known as hypo fractionated adaptive radiotherapy, was led by Dr Harjot Kaur Bajwa, Radiation Oncologist and Brachytherapy Specialist along with her team. The patient was declared cancer free at follow up and was in excellent health maintaining his quality of life.
Mr. Batra (name changed) was presented with increased urination and difficulty in passing urine for 3 months. Upon further evaluation, the patient was diagnosed with high-risk prostate cancer (advanced stage). Prostate cancer begins when cells in the prostate gland start to grow out of control.
Local symptoms associated with prostate cancer can include Lower urinary tract symptoms (LUTS), blood in urine, Erectile dysfunction or Urinary retention. The prognosis and treatment options depend on the stage of the cancer (level of PSA, Gleason score, Grade Group, how much of the prostate is affected by the cancer, and whether the cancer has spread to other places in the body.
"Delivery of advanced radiotherapy in prostate cancer is tricky because the prostate gland moves during and in between treatment. Also, the surrounding normal structures like bladder, bowel and rectum are highly mobile and may have different degree of filling every day. This can significantly affect the actual dose delivered to the normal structures and increase the side effects. "Sometimes, extreme filling of the rectum can displace the tumor out of the treatment field, and we may entirely miss the target leading to ineffective treatment," stated Dr Harjot Kaur Bajwa.
She further explained, "Since we are delivering a very high dose of radiation over a short course of time, we need to accurately localise the tumor before each treatment. With the use of daily imaging on ETHOS machine, we are able to clearly assess the position of the tumor and the normal structures. Depending upon the change in anatomy, the machine performs daily online adaptive planning which results in accurate radiation delivery and minimizes toxicity. "
Dr Prabhakar P, Regional Chief Operating Officer, AOI Hyderabad said, “Innovation and cutting-edge technology in the field of oncology are at the core of our mission at American Oncology Institute (AOI), and we are immensely proud to announce the successful treatment of an 88-year-old male battling high-risk prostate cancer. Our dedicated team's exceptional work in implementing the ETHOS – AI driven Adaptive Radiotherapy has set a remarkable standard in our commitment to patient care.
ETHOS, with its daily imaging and adaptive planning capabilities, has revolutionized our approach. The result is not only a more targeted and effective radiation delivery but also a reduction in side effects, ultimately improving the patient's quality of life. This achievement reinforces our mission to make a difference in the fight against cancer and to offer hope, healing, and a better quality of life for all those we serve.”
American Oncology Institute (AOI) at Citizens Specialty Hospital, Nallagandla in Hyderabad offers a wide range of cancer treatment services in the region. The comprehensive cancer facility, housed within the 300-bed hospital, is dedicated to delivering integrated cancer care of the highest standard, powered by clinical excellence, cutting-edge technology, and international expertise.
As a proud member of the elite global network of the International Tumor Board, AOI in Hyderabad collaborates closely with leading medical professionals worldwide. AOI Hyderabad specializes in a range of dedicated services, including Pediatric Hemato Oncology & BMT and Uro-oncology. Additionally, AOI's Comprehensive Robotic Program employs cutting-edge technology for precise surgical interventions. The advanced Pain Management ensures optimal comfort and relief during treatment, while the Critical Care service ensures round-the-clock monitoring and support for critical cases.
